Dose-Reduced [busulfan + fludarabine] Versus Standard Conditioning [busulfan + cyclophosphamide] Followed by Allogeneic Stem Cell Transplantation in Patients With MDS [myelodysplastic syndromes] or sAML [secondary acute myeloid leukaemia]: A Randomised Phase III Study (RICMAC)

Trial Profile

Dose-Reduced [busulfan + fludarabine] Versus Standard Conditioning [busulfan + cyclophosphamide] Followed by Allogeneic Stem Cell Transplantation in Patients With MDS [myelodysplastic syndromes] or sAML [secondary acute myeloid leukaemia]: A Randomised Phase III Study (RICMAC)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 May 2017

At a glance

  • Drugs Busulfan (Primary) ; Busulfan; Cyclophosphamide; Fludarabine
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Acronyms RICMAC; RICMAC MDS/sAML
  • Most Recent Events

    • 02 May 2017 Results published in the Journal of Clinical Oncology
    • 02 Apr 2015 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov record.
    • 02 Apr 2015 Status changed from active, no longer recruiting to discontinued, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top